Trial Profile
A Study Assessing the Effects of Isavuconazole on the Length of QTc Interval
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Isavuconazonium (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis; Invasive candidiasis; Mycoses; Zygomycosis
- Focus Adverse reactions
- 25 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.